Position in LYEL
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$65,138,069
-$19,786,167 QoQ
Shares Held
3,247,162
+17.7% QoQ
Ownership
13.9%
of shares outstanding
% of Portfolio
9.62%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Jun 2025
4 quarters on record
Voting authority
Sole 0.ToString("F0")%
Shared 0.ToString("F0")%
None 100.ToString("F0")%
Common Shares in LYEL Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026ARCH Venture Management, LLC holds $672,473,115 across 9 Biotechnology names. LYEL ranks #6 (9.7% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | MAZE |
Maze Therapeutics, Inc.
|
4,120,053 | $122,983,582 | |
| 2 | RAPP |
Rapport Therapeutics, Inc.
|
3,728,738 | $116,672,212 | |
| 3 | VIR |
Vir Biotechnology, Inc.
|
12,916,663 | $115,733,300 | |
| 4 | ERAS |
Erasca, Inc.
|
7,091,557 | $114,741,392 | |
| 5 | BEAM |
Beam Therapeutics Inc.
|
4,540,132 | $108,191,345 | |
| 6 | LYEL |
Lyell Immunopharma, Inc.
This page
|
3,247,162 | $65,138,069 | |
| 7 | GENB |
Generate Biomedicines, Inc.
|
1,944,426 | $24,305,325 | |
| 8 | GOSS |
Gossamer Bio, Inc.
|
8,055,916 | $2,650,396 |
All Filings in LYEL
Export CSV
4 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $65,138,069 | 3,247,162 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $84,924,236 | 2,759,072 | Shares | Sole | 2026-02-17 | |
| 2025-09-30 | $44,807,329 | 2,759,072 | Shares | Sole | 2025-11-14 | |
| 2025-06-30 | $16,094,404 | 1,820,634 | Shares | Sole | 2025-08-14 | |
| No filing history on record for this holder in this stock. | ||||||